TD Cowen analyst Yaron Werber has maintained their bullish stance on JSPR stock, giving a Buy rating today.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yaron Werber has given his Buy rating due to a combination of factors surrounding the potential and current developments of Jasper Therapeutics. The company’s drug, Briquilimab, has demonstrated strong efficacy and a clean safety profile in its trials, particularly in the treatment of chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU). Despite some anomalous data in the BEACON study, the issues have been traced not to the drug itself but to clinical site activities, which management is actively addressing.
Werber’s confidence in Jasper Therapeutics is further supported by the company’s financial position, with $51 million in cash expected to sustain operations through the first half of 2026. Although the company is slightly behind its competitors, the promising profile of Briquilimab and the attractive valuation of the stock present a favorable risk/reward scenario. As management concludes its investigation and prepares for further clinical trials, Werber maintains a positive outlook on the company’s future prospects.
Werber covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, Roivant Sciences, and BioNTech SE. According to TipRanks, Werber has an average return of 20.3% and a 60.42% success rate on recommended stocks.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $20.00 price target.